S2P-modified PLGA nanocarriers co-delivering Metformin and Evolocumab inhibit vascular senescence and foam cell formation for atherosclerosis treatment.
Background
Atherosclerosis (AS) progression is critically linked to endothelial senescence and dysregulated lipid metabolism in macrophages. Current treatments face limitations: Metformin offers vascular endothelial protection by inhibiting senescence but has limited impact on lipid metabolism. Conversely, Evolocumab, a PCSK9 inhibitor, effectively lowers LDL-C to reduce foam cell formation. A significant gap remains in therapies that can simultaneously target both endothelial senescence and macrophage lipid dysfunction, necessitating a synergistic approach to enhance treatment efficacy.
Study Design
Researchers engineered S2P peptide-modified PLGA nanocarriers (S-P@(Met+Evol) NPs) for the co-delivery of Metformin and Evolocumab. This design aimed to achieve dual targeting of pathological endothelial cells and macrophages. In vitro experiments assessed the nanoparticles' ability to reduce oxidative damage, inhibit vascular aging, and enhance macrophage cholesterol efflux. In vivo studies were conducted in an atherosclerosis model to evaluate the nanodrug's impact on aging damage, lipid accumulation, inflammatory responses, plaque burden, plaque stability, and overall safety profile.
Results
The S-P@(Met+Evol) NPs demonstrated significant therapeutic effects by addressing key pathological mechanisms of atherosclerosis. In vitro, the nanoparticles effectively reduced oxidative damage, inhibited vascular aging, and enhanced macrophage cholesterol efflux. These findings underscore the dual-targeting capabilities of the nanodrug at a cellular level. In vivo studies further corroborated these benefits, showing that the nanodrug significantly alleviated aging damage, lipid accumulation, and inflammatory responses within the vascular system. This synergistic action led to a substantial improvement in disease markers.
The S-P@(Met+Evol) NPs synergistically reduced plaque burden and enhanced plaque stability in the atherosclerosis model, while also exhibiting a good safety profile.
Key Findings
- S-P@(Met+Evol) NPs reduced oxidative damage and inhibited vascular aging
in vitro. - Nanoparticles enhanced macrophage cholesterol efflux
in vitro. In vivo, the nanodrug alleviated aging damage, lipid accumulation, and inflammatory responses.- S-P@(Met+Evol) NPs synergistically reduced plaque burden and enhanced plaque stability.
- The nanodrug exhibited a good safety profile
in vivo.
Why It Matters
This dual-cell targeted synergistic strategy represents a significant advancement for atherosclerosis treatment, offering a potential solution to the limitations of single-drug therapies. By combining Metformin's anti-senescence effects with Evolocumab's lipid-lowering capabilities via a novel S2P peptide-modified nanocarrier, this approach could lead to more comprehensive disease management. For clinicians and biohackers, this highlights the potential of multi-modal interventions to tackle complex diseases like AS by simultaneously addressing multiple pathological pathways. While preclinical, this work lays the groundwork for developing a highly effective and safer therapeutic protocol that could improve patient outcomes by not only reducing plaque but also enhancing its stability, thereby mitigating cardiovascular event risk.
atherosclerosis
metformin
evolocumab
s2p-peptide
nanomedicine
vascular-senescence